Umeclidinium
Educational summary, not a formulary. Dosing is quoted from the Makindo chapters and topics site. The other sections are draft summaries not yet checked line by line against the BNF or SPC. Check dose, indication, interactions and monitoring in the BNF entry for Umeclidinium and local guidelines before prescribing.
Long-acting antimuscarinic
Mechanism
Long-acting muscarinic antagonist.
Uses
COPD (alone or with vilanterol).
Dosing
No dose is given in the chapters. See the BNF.
Side effects
Dry mouth, urinary retention, tachycardia.
Interactions
Other anticholinergics.
Contraindications and cautions
Narrow-angle glaucoma
Monitoring
Symptoms
Pregnancy and breastfeeding
Avoid
Renal and hepatic impairment
No adjustment
Overdose and reversal
Supportive
Special advice
Check inhaler technique.
More from the textbook: uses, cautions and other points
- LABA + LAMA (e.g. umeclidinium–vilanterol, tiotropium–olodaterol) - first-line regular treatment for most people with COPD who remain breathless (NICE NG115).
Respiratory: Anatomy, Physiology and Pharmacology - LAMA - tiotropium , umeclidinium, glycopyrronium, aclidinium - once or twice daily; mainly COPD; also add-on in severe asthma.
Respiratory: Anatomy, Physiology and Pharmacology - Triple therapy (LABA + LAMA + ICS in one inhaler - e.g. fluticasone furoate–umeclidinium–vilanterol, beclometasone–formoterol–glycopyrronium) - COPD with continued exacerbations (especially with raised eosinophils or asthmatic features); severe asthma.
Respiratory: Anatomy, Physiology and Pharmacology - Tiotropium / umeclidinium (LAMA) | COPD maintenance; urinary retention, dry mouth.
Respiratory: Anatomy, Physiology and Pharmacology
Where it is discussed in the book
- Respiratory: Anatomy, Physiology and Pharmacology (4 mentions)